Maiken Keson-Brookes
2021
In 2021, Maiken Keson-Brookes earned a total compensation of $2.1M as Chief Legal Officer and Corporate Secretary at Rubius Therapeutics, a 249% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $185,120 |
|---|---|
| Option Awards | $1,138,760 |
| Salary | $413,333 |
| Stock Awards | $386,631 |
| Other | $9,290 |
| Total | $2,133,134 |
Keson-Brookes received $1.1M in option awards, accounting for 53% of the total pay in 2021.
Keson-Brookes also received $185.1K in non-equity incentive plan, $413.3K in salary, $386.6K in stock awards and $9.3K in other compensation.
Rankings
In 2021, Maiken Keson-Brookes' compensation ranked 5,812th out of 12,415 executives tracked by ExecPay. In other words, Keson-Brookes earned more than 53.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,812 out of 12,415 | 53rd |
Division Manufacturing | 2,462 out of 5,505 | 55th |
Major group Chemicals And Allied Products | 1,067 out of 2,375 | 55th |
Industry group Drugs | 950 out of 2,096 | 55th |
Industry Biological Products, Except Diagnostic Substances | 233 out of 449 | 48th |
Source: SEC filing on March 30, 2022.
Keson-Brookes' colleagues
We found four more compensation records of executives who worked with Maiken Keson-Brookes at Rubius Therapeutics in 2021.